Ana Galhoz

Ana Galhoz

Auto-generated profile, based on publicly available information

Ana Galhoz

Computational Health Center, Helmholtz Munich

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
LGLucas Caldi Gomes
Lucas Caldi Gomes
AGAna Galhoz
Ana Galhoz
GJGaurav Jain
Gaurav Jain
ARAnna‐Elisa Roser
Anna‐Elisa Roser
FMFabian Maass
Fabian Maass
Paul LingorPaul Lingor
Paul Lingor
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder whose prevalence is rapidly increasing worldwide. The molecular mechanisms underpinning the pathophysiology of sporadic PD remain incompletely understood. Therefore, causative therapies are still elusive. To obtain a more integrative view of disease‐mediated alterations, we investigated the molecular landscape of PD in human post‐mortem midbrains, a region that is highly affected during the disease process.Methods: Tissue from 19 PD patients and 12 controls were obtained from the Parkinson's UK Brain Bank and subjected to multi‐omic analyses: small and total RNA sequencing was performed on an Illumina's HiSeq4000, while proteomics experiments were performed in a hybrid triple quadrupole‐time of flight mass spectrometer (TripleTOF5600+) following quantitative sequential window acquisition of all theoretical mass spectra. Differential expression analyses were performed with customized frameworks based on DESeq2 (for RNA sequencing) and with Perseus v.1.5.6.0 (for proteomics). Custom pipelines in R were used for integrative studies.Results: Our analyses revealed multiple deregulated molecular targets linked to known disease mechanisms in PD as well as to novel processes. We have identified and experimentally validated (quantitative real‐time polymerase chain reaction/western blotting) several PD‐deregulated molecular candidates, including miR‐539‐3p, miR‐376a‐5p, miR‐218‐5p and miR‐369‐3p, the valid miRNA‐mRNA interacting pairs miR‐218‐5p/RAB6Cand miR‐369‐3p/GTF2H3, as well as multiple proteins, such as CHI3L1, HSPA1B, FNIP2 and TH. Vertical integration of multi‐omic analyses allowed validating disease‐mediated alterations across different molecular layers. Next to the identification of individual molecular targets in all explored omics layers, functional annotation of differentially expressed molecules showed an enrichment of pathways related to neuroinflammation, mitochondrial dysfunction and defects in synaptic function.Conclusions: This comprehensive assessment of PD‐affected and control human midbrains revealed multiple molecular targets and networks that are relevant to the disease mechanism of advanced PD. The integrative analyses of multiple omics layers underscore the importance of neuroinflammation, immune response activation, mitochondrial and synaptic dysfunction as putative therapeutic targets for advanced PD.

4 December 2020 in eLife
Verified
Journal Article
Open access
DWDennis Wang
Dennis Wang
JHJames Hensman
James Hensman
GKGinte Kutkaite
Ginte Kutkaite
TTTzen S Toh
Tzen S Toh
AGAna Galhoz
Ana Galhoz
FDFrank Dondelinger
Frank Dondelinger
High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. However, the cells’ response to a drug is typically quantified by a summary statistic from a best-fit dose-response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage uncertainty estimates to identify associated biomarkers with a new Bayesian framework. Applied to in vitro screening data on 265 compounds across 1074 cancer cell lines, our models identified 24 clinically established drug-response biomarkers, and provided evidence for six novel biomarkers by accounting for association with low uncertainty. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to any dose-response data without replicates, and improves biomarker discovery for precision medicine.

1 August 2020 in Patterns
Verified
Journal Article
Open access
IAIñigo Ayestaran
Iñigo Ayestaran
AGAna Galhoz
Ana Galhoz
ESElmar Spiegel
Elmar Spiegel
BSBen Sidders
Ben Sidders
JDJonathan R. Dry
Jonathan R. Dry
MMMichael P. Menden
Michael P. Menden
High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations carrying sensitivity biomarkers and consecutively investigate unexpectedly resistant (UNRES) cell lines for unique genetic alterations that may drive resistance. By analyzing the GDSC and CTRP datasets, we find 53 and 35 UNRES cases, respectively. For 24 and 28 of them, we highlight putative resistance biomarkers. We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors. Interrogating the underpinnings of drug resistance with publicly available CRISPR phenotypic assays assists in prioritizing resistance drivers, offering hypotheses for drug combinations.

30 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ICIsabell Cordts
Isabell Cordts
AGAna Galhoz
Ana Galhoz
Laura TzeplaeffLaura Tzeplaeff
Laura Tzeplaeff
AGAnne Gründel
Anne Gründel
FKFlorian Kohlmayer
Florian Kohlmayer
Paul LingorPaul Lingor
Paul Lingor
Neurodegenerative diseases often feature a prolonged presymptomatic phase during which pathological processes evolve before overt clinical manifestation. In Amyotrophic lateral sclerosis (ALS), defining this prodromal period is critical for identifying early disease features and the optimal window for intervention, yet it remains poorly characterised. In this cross-sectional study, we compared 475 ALS patients with 285 controls recruiting across 20 ALS expert centres in Germany and Switzerland. Participants completed a structured digital questionnaire capturing prodromal complaints, healthcare utilisation, comorbidities, lifestyle factors, and weight changes during the 10 years preceding ALS symptom onset. ALS patients reported substantially higher burden of prodromal complaints than controls (OR=7.50, 95% CI 4.27-13.17; P < 0.001; P adj < 0.001), particularly neuro-motor, sensory, and pain-related symptoms. Prior to symptom onset, ALS patients more frequently consulted neurologists (OR=1.26, CI 1.10-1.44; P < 0.001; P adj = 0.007). Speech therapy consultations were significantly more common among female patients (OR = 2.35, CI 1.05–5.28; P = 0.038) and those with bulbar-onset ALS (OR = 8.67, CI 3.80–19.77; P < 0.001). Prodromal musculoskeletal dysfunction was more frequently reported by ALS patients and exhibited sex- and site-specific patterns. Herniated discs were reported more often by male ALS patients (OR=2.21, CI 1.04-4.68; P = 0.038) and by those with spinal-onset disease (OR=2.32, CI 1.38-3.93; P = 0.002). ALS patients more often completed lower secondary education (OR=1.93, CI 1.24-3.01; P = 0.004; P adj = 0.020) and were more likely to have worked in physically demanding occupations (OR=2.21, CI 1.42-3.43; P < 0.001; P adj = 0.003). Lifestyle factors differed significantly, with higher prior consumption of caffeine (OR=7.21, CI 3.27–15.89; P < 0.001; P adj < 0.001), alcohol (OR=2.25, CI 1.47–3.43; P < 0.001; P adj = 0.002), and cigarettes (OR=1.64, CI 1.20–2.24; P = 0.002) among ALS patients ( P adj = 0.011). Weight trajectories differed by sex ( P = 0.009), with male ALS patients showing significant loss already during the pre-onset phase ( P < 0.001). These findings demonstrate that ALS is preceded by a distinct prodromal phase characterised by mild motor impairment, altered healthcare engagement, and sex- and site-specific patterns in comorbidities, lifestyle, and metabolic change. Characterising these early features of ALS may facilitate earlier diagnosis and enable timely enrolment in clinical trials.

4 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
Laura TzeplaeffLaura Tzeplaeff
Laura Tzeplaeff
XLXuan Liu
Xuan Liu
CMClara Meijs
Clara Meijs
LGLucas Caldi Gomes
Lucas Caldi Gomes
AGAna Galhoz
Ana Galhoz
PLPaul Lingor
Paul Lingor
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease, yet therapeutic progress remains slow due to pronounced biological heterogeneity. Here, we present a high-resolution proteomic map of cerebrospinal fluid (CSF) in a clinically well-characterized cohort of 93 individuals with ALS and 101 controls, defining molecular differences. Building on this landscape, unsupervised analysis revealed two reproducible ALS subtypes: an immune-enriched alpha subtype and a synapto-axonal beta subtype, further validated in an independent cohort (n=43 ALS). The alpha subtype was associated with higher neurofilament concentrations, whereas the beta subtype showed slower disease progression, indicating distinct pathological trajectories. We further derived a five-protein classifier (PARK7, PTPRS, ATRN, CNTN1, PCSK1N) that robustly discriminated subtypes across cohorts (AUC 0.951 ± 0.007). Together, this work defines the CSF proteomic landscape of ALS and establishes a foundation for molecular stratification in precision therapy and clinical trial design.

9 October 2026 in EBioMedicine
Verified
Journal Article
Open access
ICIsabell Cordts
Isabell Cordts
AGAna Galhoz
Ana Galhoz
Laura TzeplaeffLaura Tzeplaeff
Laura Tzeplaeff
AGAnne Gründel
Anne Gründel
FKFlorian Kohlmayer
Florian Kohlmayer
Paul LingorPaul Lingor
Paul Lingor